BioDelivery Sciences International Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/12/2022)
| Balance Sheet | Total Assets | 324,596,000.00 | ROE | – |
| Balance Sheet | Total Equity | 187,822,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -415,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 40,622,000.00 | – | – |
| Cashflow | Operating Cash Flow | 41,037,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 0.82 | Div. Yield | – |
| Income | Net Income | 84,860,000.00 | P/E | – |
| Income | Shares Outstanding | 102,431,000.00 | P/B | – |
| Income | Total Revenue | 29,923,186.57 | P/S | – |
Ratios calculated on: –
Company Description
BioDelivery Sciences International, Inc. (BDSI) is a specialty pharmaceutical company. BDSI is developing and commercializing, either on its own or in partnerships with third parties, applications of therapeutics to address medical needs. The Company has developed and is continuing to develop pharmaceutical products aimed principally in the areas of pain management and oncology supportive care. In formulating the Company´s products and product candidates, BDSI utilizes the BioErodible MucoAdhesive (BEMA) drugs delivery technology, a small, erodible polymer film for application to the buccal mucosa. The Company´s the United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its pipeline of product candidates, utilize its BEMA technology.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.bdsi.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more